Non-interventional study concerning efficacy and safety of the intraperitoneal therapy with Removab(R) under routine practice conditions: Ambulant Catumaxomab Therapy: ACT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000712

Enrollment

Registered

2011-03-04

Start date

2011-06-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malign Ascites R18

Interventions

Group 1: Observation group: Intraperitoneal infusion of Removab(R).

Eligibility

Sex/Gender

Female

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Malign Ascites. Patients can be included on first diagnosis and treatment recommendation with Removab(R) by the physician

Exclusion criteria

Exclusion criteria: By physician's judgement

Design outcomes

Primary

Measure	Time frame
Puncture-free interval after last Removab infusion	—

Secondary

Measure	Time frame
Quality of life regarding Ascites symptoms. Time of measurement: Infusions 1 - 4 and follow-ups 1 and 2. Method of measurement: FACIT Ascites questionnaire.	—

Countries

Germany

Contacts

Public ContactHeribert Stiegler

OnkoDataMed GmbH

heribert.stiegler@onkodatamed.de030 / 64 38 75 60

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026